Ser403

Site Information
VQMNRNLsNEELtKS SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 467846

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 )
Disease tissue studied:	breast cancer ( 7 , 8 , 15 , 16 , 37 , 38 , 39 , 40 , 41 ) , breast ductal carcinoma ( 7 , 37 , 38 , 39 , 40 , 41 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 7 ) , cervical cancer ( 30 ) , cervical adenocarcinoma ( 30 ) , leukemia ( 43 ) , chronic myelogenous leukemia ( 43 ) , lung cancer ( 10 , 16 , 25 ) , non-small cell lung cancer ( 16 ) , non-small cell lung adenocarcinoma ( 10 , 25 ) , neuroblastoma ( 14 ) , ovarian cancer ( 7 ) , pancreatic ductal adenocarcinoma ( 9 ) , melanoma skin cancer ( 5 )
Relevant cell line - cell type - tissue:	'muscle, skeletal' ( 20 ) , 'pancreatic, ductal'-pancreas ( 9 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 28 ) , 293 (epithelial) ( 21 , 22 , 23 , 36 ) , 293E (epithelial) ( 24 ) , A498 (renal) ( 29 ) , A549 (pulmonary) ( 11 ) , breast ( 2 , 7 ) , BT-20 (breast cell) ( 16 ) , BT-549 (breast cell) ( 16 ) , endothelial-aorta ( 17 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 18 ) , Flp-In T-Rex-293 (epithelial) ( 18 ) , H2009 (pulmonary) ( 16 ) , H2077 (pulmonary) ( 16 ) , H2887 (pulmonary) ( 16 ) , H322M (pulmonary) ( 16 ) , HCC1359 (pulmonary) ( 16 ) , HCC1937 (breast cell) ( 16 ) , HCC2279 (pulmonary) ( 16 ) , HCC366 (pulmonary) ( 16 ) , HCC4006 (pulmonary) ( 16 ) , HCC78 (pulmonary) ( 16 ) , HCC827 (pulmonary) ( 16 ) , HEK293T (epithelial) ( 4 ) , HeLa (cervical) ( 6 , 13 , 27 , 31 , 45 ) , HeLa S3 (cervical) ( 30 ) , HepG2 (hepatic) ( 34 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 8 ) , HMLER ('stem, breast cancer') ( 8 ) , HOP62 (pulmonary) ( 16 ) , HUES-9 ('stem, embryonic') ( 26 ) , Jurkat (T lymphocyte) ( 44 ) , K562 (erythroid) ( 13 , 31 , 43 ) , LCLC-103H (pulmonary) ( 16 ) , LOU-NH91 (squamous) ( 16 ) , lung ( 10 ) , MCF-7 (breast cell) ( 16 , 37 , 38 , 39 , 40 , 41 , 42 ) , MDA-MB-231 (breast cell) ( 16 ) , MDA-MB-468 (breast cell) ( 16 ) , NB10 (neural crest) ( 14 ) , NCI-H1395 (pulmonary) ( 16 ) , NCI-H1568 (pulmonary) ( 16 ) , NCI-H157 (pulmonary) ( 16 ) , NCI-H1666 (pulmonary) ( 16 ) , NCI-H2030 (pulmonary) ( 16 ) , NCI-H2172 (pulmonary) ( 16 ) , NCI-H2228 (pulmonary) ( 32 , 33 ) , NCI-H322 (pulmonary) ( 16 ) , NCI-H3255 (pulmonary) ( 35 ) , NCI-H460 (pulmonary) ( 16 ) , NCI-H520 (squamous) ( 16 ) , NCI-H647 (pulmonary) ( 16 ) , NPC (neural crest) ( 14 ) , ovary ( 7 ) , PC9 (pulmonary) ( 16 ) , SKBr3 (breast cell) ( 15 ) , U-1810 (pulmonary) [EFNB3 (human), knockdown] ( 25 ) , U-1810 (pulmonary) ( 25 ) , Vero E6-S ('epithelial, kidney') ( 1 ) , WM239A (melanocyte) ( 5 )

Upstream Regulation
Treatments:	ischemia ( 7 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
4	Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23 25278378 Curated Info
5	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
6	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
7	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
8	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
9	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
10	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
11	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
12	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
13	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
14	DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513 24349301 Curated Info
15	Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57 22964224 Curated Info
16	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
17	Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81 22497526 Curated Info
18	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
19	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
20	Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876 22673903 Curated Info
21	Mulhern D (2011) CST Curation Set: 12828; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS/T) Immunoaffinity Beads Cat#: 5760 Curated Info
22	Mulhern D (2011) CST Curation Set: 12830; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS/T) Immunoaffinity Beads Cat#: 5760 Curated Info
23	Mulhern D (2011) CST Curation Set: 12831; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) AMPK Substrate (P-S/T(2)-102) Rabbit mAb Cat#: 5759, PTMScan(R) Phospho-AMPK Substrate Motif (LXRXXS/T) Immunoaffinity Beads Cat#: 5760 Curated Info
24	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
25	Ståhl S, et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566-78 21413766 Curated Info
26	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
27	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
28	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
29	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
30	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
31	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
32	Possemato A (2009) CST Curation Set: 7398; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
33	Possemato A (2009) CST Curation Set: 7397; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
34	Possemato A (2009) CST Curation Set: 7395; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
35	Possemato A (2009) CST Curation Set: 7399; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
36	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
37	Possemato A (2008) CST Curation Set: 5240; Year: 2008; Biosample/Treatment: cell line, MCF-7/serum starved; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
38	Possemato A (2008) CST Curation Set: 5242; Year: 2008; Biosample/Treatment: cell line, MCF-7/serum starved; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
39	Possemato A (2008) CST Curation Set: 5243; Year: 2008; Biosample/Treatment: cell line, MCF-7/untreated; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
40	Possemato A (2008) CST Curation Set: 5239; Year: 2008; Biosample/Treatment: cell line, MCF-7/serum starved; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
41	Possemato A (2008) CST Curation Set: 5241; Year: 2008; Biosample/Treatment: cell line, MCF-7/serum starved; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
42	Possemato A (2008) CST Curation Set: 5250; Year: 2008; Biosample/Treatment: cell line, MCF-7/untreated; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
43	Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
44	Stokes M (2008) CST Curation Set: 3884; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
45	Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92 16964243 Curated Info